We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 247

Prohibition granted re the compound patent; dismissed re use and polymorph patents

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This NOC proceeding deals with challenges to three patents, a compound patent, a use patent and a polymorph patent

Product specificity is the same for different types of claims in listing on the Patent Register

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

Teva brought a motion pursuant to section 6(5)(a) of the Patented Medicines (Notice of Compliance) Regulations relating to the listing of a patent on

Court bifurcates determination of Start Date for section 8 action

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 30 2014

This is an action commenced pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations. Pfizer counterclaimed against Apotex

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The PMPRB has published a new analytical report: Utilization of Prescription Opioids in Canada's Public Drug Plans, 200607 to 201213

Supreme Court denies Apotex leave to appeal; prohibition order stands

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

The Supreme Court of Canada (SCC) denied Apotex leave to Appeal the decision of the Federal Court of Appeal (FCA) in a s. 8 case (decision here

Oder of prohibition issues no promise to treatment in humans or reduced side effects was found

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 30 2014

Pfizer’s Canadian Patent No. 2,177,576 for Celebrex has withstood Apotex’s allegations and was found to be valid; therefore the Minister is

The Court grants an innovator standing and the right to be made a party in a judicial Review of the Minister’s Decision relating to the application of the data protection regime

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 26 2014

This was a motion that raised the issue of an innovator’s standing and right to be made a party to a judicial review of the Minister of Health’s

Patent to an “expandable and contractible hose” found to be obvious

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 16 2014

One of the plaintiffs in this patent infringement suit is the inventor of Canadian Patent No. 2,779,882, a patent that claims a compact garden hose

Hypothetical world when multiple s. 8 damages cases held not to reflect size of actual generic market

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 4 2014

In May, 2012, the Federal Court quantified damages owed to Apotex pursuant to s. 8 of the NOC Regulations (decision here, summary here). Similarly

Appeals dismissed from quantification of s. 8 damages

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 4 2014

As discussed above, in May 2012, the Federal Court quantified damages owed to Apotex and Teva pursuant to s. 8 of the NOC Regulations. (Teva decision